Literature DB >> 10674678

Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.

A Vargas-Gonzalez1, S B Canto-Lara, A G Damian-Centeno, F J Andrade-Narvaez.   

Abstract

Cutaneous leishmaniasis, known as chiclero's ulcer in southeastern Mexico, is characterized by a predominantly single, painless, ulcerated lesion, without lymphangitis or adenopathy. When located on the ear, it tends to become chronic, causing destruction of the pinna and disfigurement. It is caused predominantly by Leishmania (L.) mexicana. Although pentavalent antimonials (Sb5+) are the mainstay of leishmanial therapy and have been used for more than 50 years, dosage regimens have been repeatedly modified and the best one has not been fully identified. The main purpose of the present study was to investigate the response of chiclero's ulcer to treatment with meglumine antimoniate. One hundred five patients were treated with meglumine antimoniate at a daily dose of 1 ampule per day (425 mg of Sb5+) until healing. The lesions healed after a mean of 25 days (range = 5-60 days).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10674678     DOI: 10.4269/ajtmh.1999.61.960

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Cutaneous leishmaniasis in a returning traveller.

Authors:  Eric Demers; David M Forrest; Gabriele E Weichert
Journal:  CMAJ       Date:  2013-03-25       Impact factor: 8.262

Review 3.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

4.  Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.

Authors:  Ricardo Obonaga; Olga Lucía Fernández; Liliana Valderrama; Luisa Consuelo Rubiano; Maria Del Mar Castro; Maria Claudia Barrera; Maria Adelaida Gomez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

5.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

6.  NRAMP1 Polymorphisms like Susceptibility Marker in Mexican Focus of Cutaneous Leishmaniasis.

Authors:  Mirsha Pamela Hernández-Rivera; Alicia Ramírez-Ramírez; Adelaido Chiñas-Pérez; Amalia Monroy-Ostria; Mario Eugenio Cancino-Díaz; Omar Hernández-Montes
Journal:  Biomed Res Int       Date:  2016-10-18       Impact factor: 3.411

7.  Ecology of phlebotomine sandflies and putative reservoir hosts of leishmaniasis in a border area in Northeastern Mexico: implications for the risk of transmission of Leishmania mexicana in Mexico and the USA.

Authors:  Jorge J Rodríguez-Rojas; Ángel Rodríguez-Moreno; Miriam Berzunza-Cruz; Gabriel Gutiérrez-Granados; Ingeborg Becker; Victor Sánchez-Cordero; Christopher R Stephens; Ildefonso Fernández-Salas; Eduardo A Rebollar-Téllez
Journal:  Parasite       Date:  2017-08-21       Impact factor: 3.000

Review 8.  Leishmaniasis: a review.

Authors:  Edoardo Torres-Guerrero; Marco Romano Quintanilla-Cedillo; Julieta Ruiz-Esmenjaud; Roberto Arenas
Journal:  F1000Res       Date:  2017-05-26

9.  Preliminary epidemiological findings of Leishmania infection in the municipality of Tinum, Yucatan State, Mexico.

Authors:  Elsy Nalleli Loría-Cervera; Erika Ivett Sosa-Bibiano; Nicole R Van Wynsberghe; Jimmy Raymundo Torres-Castro; Fernando José Andrade-Narváez
Journal:  Parasite Epidemiol Control       Date:  2019-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.